US Bancorp DE Acquires 819 Shares of iRadimed Corporation $IRMD

US Bancorp DE lifted its position in shares of iRadimed Corporation (NASDAQ:IRMD) by 132.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,436 shares of the medical equipment provider’s stock after acquiring an additional 819 shares during the period. US Bancorp DE’s holdings in iRadimed were worth $75,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. First Horizon Advisors Inc. lifted its stake in iRadimed by 78.7% in the 1st quarter. First Horizon Advisors Inc. now owns 513 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 226 shares during the last quarter. State of Wyoming bought a new position in iRadimed in the 4th quarter valued at approximately $149,000. Snowden Capital Advisors LLC bought a new position in iRadimed in the 4th quarter valued at approximately $229,000. Wells Fargo & Company MN lifted its stake in iRadimed by 41.1% in the 4th quarter. Wells Fargo & Company MN now owns 4,362 shares of the medical equipment provider’s stock valued at $240,000 after purchasing an additional 1,270 shares during the last quarter. Finally, Zacks Investment Management bought a new position in iRadimed in the 4th quarter valued at approximately $248,000. Institutional investors own 92.34% of the company’s stock.

iRadimed Stock Performance

Shares of NASDAQ IRMD opened at $70.11 on Tuesday. iRadimed Corporation has a 52-week low of $43.17 and a 52-week high of $73.47. The firm has a 50 day moving average price of $61.48 and a two-hundred day moving average price of $56.64. The stock has a market cap of $891.80 million, a P/E ratio of 43.28 and a beta of 0.94.

iRadimed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 28th. Shareholders of record on Monday, August 18th will be given a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 1.0%. The ex-dividend date is Monday, August 18th. iRadimed’s dividend payout ratio is 41.98%.

Insider Transactions at iRadimed

In other iRadimed news, Director Monty K. Allen sold 1,102 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $69.10, for a total value of $76,148.20. Following the completion of the transaction, the director directly owned 19,898 shares in the company, valued at approximately $1,374,951.80. This represents a 5.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 36.80% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of iRadimed from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 6th.

iRadimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.